S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:ALNA

Allena Pharmaceuticals - ALNA Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
$0.02
$0.16
52-Week Range
N/A
Volume
7.91 million shs
Average Volume
15.69 million shs
Market Capitalization
$1.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
ALNA stock logo

About Allena Pharmaceuticals (NASDAQ:ALNA) Stock

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Receive ALNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNA Stock News Headlines

ALNA.O
Nano cap stock Allena surges on heavy volume
Allena Pharmaceuticals $2.8M direct offering
Why Are Allena Pharma Shares Plunging Today
Allena Pharmaceuticals, Inc. (ALNA)
Allena Pharmaceuticals, Inc.(ALNA)
See More Headlines

Receive ALNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNA Company Calendar

Last Earnings
3/31/2022
Today
12/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALNA
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-48,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.23 per share

Miscellaneous

Free Float
117,566,000
Market Cap
$1.95 million
Optionable
Not Optionable
Beta
1.13

Key Executives

  • Dr. Alexey L. Margolin Ph.D. (Age 69)
    Co-Founder & Chairman
    Comp: $70k
  • Dr. Louis Brenner M.B.A. (Age 52)
    M.D., Pres, CEO & Director
    Comp: $576.86k
  • Dr. Richard D. Katz (Age 58)
    CFO, Principal Financial Officer & Principal Accounting Officer
    Comp: $400.67k
  • Mr. Robert Gallotto (Age 57)
    Co-Founder & Strategic Adviser
  • Mr. Geoffrey A. Swire (Age 49)
    Sr. VP of Corp. Devel., Acting COO & Interim Principal Operating Officer
  • Mr. Hugh Wight
    Sr. VP of Technical Operations
  • Dr. Alicja Januszewicz Ph.D.
    VP of People & Culture
  • Dr. David J. Clark (Age 57)
    Chief Medical Officer













ALNA Stock - Frequently Asked Questions

Should I buy or sell Allena Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALNA, but not buy additional shares or sell existing shares.
View ALNA analyst ratings
or view top-rated stocks.

What is Allena Pharmaceuticals' stock price forecast for 2023?

3 Wall Street analysts have issued 12 month target prices for Allena Pharmaceuticals' shares. Their ALNA share price forecasts range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next year.
View analysts price targets for ALNA
or view top-rated stocks among Wall Street analysts.

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) released its earnings results on Thursday, March, 31st. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.06.

What is Louis Brenner, M.D.'s approval rating as Allena Pharmaceuticals' CEO?

1 employees have rated Allena Pharmaceuticals Chief Executive Officer Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among the company's employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN).

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Allena Pharmaceuticals' stock symbol?

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

How much money does Allena Pharmaceuticals make?

Allena Pharmaceuticals (NASDAQ:ALNA) has a market capitalization of $0.00.

How can I contact Allena Pharmaceuticals?

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The official website for the company is www.allenapharma.com. The company can be reached via phone at (617) 467-4577, via email at hannah.deresiewicz@sternir.com, or via fax at 617-916-1871.

This page (NASDAQ:ALNA) was last updated on 12/2/2022 by MarketBeat.com Staff